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Androgen receptor coactivator p120 subtype β is highly 
expressed in prostate cancer
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Purpose: The β form of p120 is reported to be a strong coactivator of the androgen receptor. We investigated the gene expression 
profiles of the α and β forms of p120 in prostate cancer cell lines, benign prostatic hyperplasia (BPH), nontreated prostate cancer (NTPC), 
and prostate cancer after androgen deprivation therapy (PCA-ADT).
Methods: We obtained 154 prostate needle biopsy specimens (81 in BPH, 51 in NTPC, and 22 in PCA-ADT). Levels of p120α and β 
expression were determined by multiplex real-time polymerase chain reaction.
Results: Prostate cancer cell lines, LNCaP, PC-3, DU-145 and LNCaP-LA, which is a derivative of LNCaP under androgen deprivation, 
expressed both p120α and p120β. p120α expression levels were significantly higher than those of p120β in all cell lines examined. In 
human prostate tissues, p120α expression was significantly higher than that of p120β in BPH and NTPC. p120α expression in BPH was 
significantly higher than in other groups. In contrast, p120β expression was significantly higher in NTPC and PCA-ADT than in BPH. 
Expression of the two forms of p120 was not correlated with age, prostate-specific antigen, or Gleason score.
Conclusions: The expression profiles of p120α and p120β significantly differ in cancerous and benign prostatic tissues.
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INTRODUCTION
Prostate cancer is one of the most common types of cancer, 
and is second only to lung cancer as the most common non-
cutaneous cancer diagnosed in males in the United States [1]. 
In Japan, the incidence of prostate cancer is increasing rap-
idly [2]. Curative options for prostate cancer include surgery, 
radiotherapy, and androgen deprivation therapy (ADT). Hug-
gins and Hodges [3] treated a patient with progressive pros-
tate cancer by castration in 1941, and administration of ADT 
improved his condition. ADT has since been widely used as 
the gold standard for prostate cancer.
 Prolonged treatment is, however, limited by the develop-
ment of resistance. ADT with luteinizing hormone-releasing 
hormone agonist, alone or combined with an antiandrogenic 
agent, is the most widely performed hormonal therapy. Vari-
ous mechanisms of reduced susceptibility to ADT have been 
proposed. These include over-expression of androgen recep-
tors (AR) [4], variations in AR [5], activation of ARs that do 
not bind androgens and other hormones [6], and cofactor 
abnormalities involving androgen production within prostate 
cancer cells [7]. AR associates with coactivator or corepres-
sor proteins that modulate its activation in the presence of 
ligand. Alterations in AR coactivator expression or function in 
prostate cancer include colocalization with AR in aggregates 
(mutated AR) [8], potentiation of the agonistic effect of hy-
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droxyflutamide [9], and potentiation of various AR activations 
[10]. Increased expression of steroid receptor coactivator-1 
(SRC-1) and transcriptional intermediary factors-2 (TIF-2), 
which are AR coactivators, has been reported in castration-
refractory prostate cancer (CRPC) tissue, and RAC-3 (SRC-3) 
expression is reportedly increased in poorly differentiated car-
cinomas and advanced tumors. Other cofactors (e.g., competi-
tive protein binding, androgen receptor activation [ARA]70, 
ARA55) showing altered expression in prostate cancer have 
also been identified [7].
 A nuclear general receptor coactivator, p120, was origi-
nally cloned as a coactivator of thyroid receptor (TR) [11]. 
p120 consisted of 920 amino acids and showed significant 
homology to skeletal muscle abundant protein. Various hu-
man tissues express p120 mRNA, including the heart, brain, 
placenta, lung, liver, skeletal muscle, kidney, and pancreas. 
A novel splice variant of p120 (p120α), p120β was cloned in 
our university [12], and has been reported to be the strong co-
activator of AR. In most tissues, p120β expression levels were 
lower than those of p120α, whereas prostate tissues express 
predominantly p120β. The authors suggested that p120β af-
fects hormone sensitivity in prostate cancer. However, analysis 
of the expression patterns of p120α and p120β were based on 
semiquantitative real time polymerase chain reaction (PCR) 
using as a small number of prostate samples. In the present 
study, we developed a more accurate quantification method, 
using multiplex real time PCR, and evaluated the expression 
profiles of p120α and p120β in large numbers of samples to 
confirm the role of p120 in prostate cancer.
MATERIALS AND METHODS
1. Cells and chemicals
The human prostate cancer cell lines LNCaP, PC-3, and DU145 
were purchased from the American Type Culture Collection 
(Manassas, VA, USA). DU145 were cultured in Dulbecco’s 
modified eagle medium (Sigma-Aldrich Co., St. Louis, MO, 
USA), and PC-3 and LNCaP in RPMI-1640 (Sigma-Aldrich 
Co.), supplemented with 10% fetal bovine serum (FBS; More-
gate Biotech, Bulimba, Australia). LNCaP-LA was used as an 
in vitro model of CRPC, and were derived from LNCaP cells 
cultured with 10% charcoal-stripped FBS for 2 years. The 
RNeasy Mini kit (QIAGEN, Chatsworth, CA, USA) was used 
for RNA isolation and cDNA was synthesized using moloney 
murine leukemia virus reverse transcriptase and random 
primers (Invitrogen, Life Technologies Co., Carlsbad, CA, 
USA) according to the manufacturer’s protocols [13].
2.  Multiplex real time PCR for p120α and p120β detec-
tion
We designed specific primers for detection of p120α and 
p120β (Fig. 1). As an internal control, 18S RNA copy numbers 
were determined. The p120α and p120β 18S RNA primer sets 
are shown in Table 1. The 18S1 set was for p120α, and the 
18S2 set for p120β. Multiplex real time PCR was performed 
using 2×  iQSupermix (Bio-Rad Laboratories Inc., Hercules, 
CA, USA), using 300 nM of each p120 primer, 200 nM p120 
probe, 300 nM of each 18S primer, 200 nM 18S probe, 2.4 µL 
of water, and 1 µL of the template. PCR was carried out for 40 
cycles at 95°C for 5 seconds, 60°C for 10 seconds, and 95°C 
for 10 seconds. The real time PCR assays were carried out in 
96-well plates using CFX96 (Bio-Rad Laboratories Inc.). Stan-
dard curves for each transcript are shown in Fig. 2.
Table 1. Primer and probe sequences
Primer Sequence
p120α
Sense primer 5’-CCACTATGGAAGAGGCTA-3’
Antisense primer 5’-TCAGGAATCCCAGGAAAC-3’
Probe 5’-FAM-ACTTTGCCG-ZEN-AGTACCCCAGTCA-
BkFQ-3’
P120β
Sense primer 5’-CCAACCACTATGGAAGAG-3’
Antisense primer 5’-GACACCTGTACTGTTCAG-3’
Probe 5’-FAM-AGCCACAGC-ZEN-CATTTCACTCTCA-
BkFQ-3’
18s1
Sense primer 5’-CCATCACTGCCATTAAGG -3’
Antisense primer 5’-AGGTCAATGTCTGCTTTC -3’
Probe 5’-Cy5-ACACCACATGAGCATATCTTCGGC-IAbRQ-3’
18s2
Sense primer 5’-CGAAGATATGCTCATGTG -3’
Antisense primer 5’- CATCCTTCTGTCTGTTCA-3’
Probe 5’-Cy5-AAGCAGACATTGACCTC-ACCAAGA-
IAbRQ-3’ 
Exon8 Exon10
p120β
S P A
S
p120α
Exon8 Exon9 Exon10
P A
Fig. 1. Schema of p120α and p120β. In p120α, we designed an 
antisense primer and probe on exon 9, while probe p120β was 
designed on the junction of exons 9 and 10. S, sense primer; A, 
antisense primer;  P, probe.
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3. Prostate biopsy specimens
All prostate biopsy specimens were obtained at the Gunma 
University Hospital between 2002 and 2009, as described pre-
viously [14]. Written informed consent was obtained from all 
patients. Fifty one nontreated prostate cancer (NTPC) sam-
ples, 81 benign prostatic hyperplasia (BPH) samples, and 22 
prostate cancer samples that had many viable cells remaining 
after ADT for 6 months prostate cancer after androgen de-
privation therapy (PCA-ADT) were obtained. Prostate biopsy 
after 6 months of ADT was intended for pathological evalua-
tion of ADT. Table 2 shows the characteristics of the patients. 
NTPC and PCA-ADT samples were selected based on their 
mulitple positive cores. 
4. Statistical analyses
Differences between the two groups were evaluated using 
the Student’s t-test. A two-sided P-value of less than 0.05 was 
considered to indicate statistical significance.
RESULTS
1.  p120α and β expression profiles in prostate cancer 
cell lines (Table 3)
Both p120α and β were expressed in all four cell lines. p120α, 
p120β, and β/α expression values are expressed as relative 
ratios vs. those of p120α in LNCaP. The expression levels of 
p120α showed no significant differences among the four cell 
lines. LNCaP-LA expressed p120β at a significantly higher 
level than PC-3 (P<0.05) or DU145 (P<0.01). β/α ratios were 
not significantly different among the four cell lines.
2.  p120α and p120β expression profiles in human 
prostate tissues
In prostate cancer cell lines, p120α was expressed at a sig-
nificantly higher level than p120β. Next, we compared the 
expression levels in human prostate cancer tissues. As shown 
in Fig. 3, expression levels of p120α were significantly higher 
than those of p120β in the BPH and NTPC groups, while there 
was no significant difference in the PCA-ADT group.
Table 2. Patients’ characteristics
Characteristic BPH NTPC PCA-ADTa)
No. of patients 81 51 22
Age (yr) 64.8 (46–85) 70.2 (55–86) 68.0 (50–78)
Prostate-specific 
antigen
7.28 (1–40.8) 91.1 (0.5–1,408) 386.1 (0.1–4,620)
Gleason score Unknown 6
6 11 4
7 11 10
8 8 1
9 10 4
10 11 0
Values are presented as mean (range).
BPH, benign prostatic hypertrophy; NTPC, nontreated prostate cancer; 
PCA-ADT, prostate cancer after androgen deprivation therapy.
a)Prostate cancer samples with many viable cells remaining after ADT 
for 6 months.
Table 3. Relative expression levels of p120α and p120β in pros-
tate cancer cell lines
p120α p120β β/α ratio
LNCaP 1.000±0.936a) 0.089±0.109 0.138±0.121
LNCaPLA 3.136±5.152 0.057±0.010 0.099±0.085
DU145 0.535±0.833 0.007±0.003 0.064±0.075
PC3 0.304±0.277 0.021±0.026 0.144±0.221
Values are presented as mean±standard deviation. Values of p120α, 
p120β and β/α are presented as relative ratios vs. those of p120α in LN-
CaP (n=3). 
a)Reference.
Fig. 2. Standard curves for real-time polymerase chain reaction. 
(A) p120α 5.32E+8 copies, 5.32E+6 copies, 5.32E+4 cop-
ies, 5.32E+2 copies, and 18s rRNA;  6.12E+8 copies,  
6.12E+6 copies,  6.12E+4 copies, and  6.12E+2 copies. (B) 
p120β 5.27E+8 copies, 5.27E+6 copies, 5.27E+4 copies, 
5.27E+2 copies, and 18srRNA;  4.83E+8 copies,  4.83E+6 
copies,  4.83E+4 copies, and  4.83E+2 copies. RFU, relative 
fluorescence units.
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 Next, we compared expression levels of p120α and p120β, 
and β/α ratios among three groups. As shown in Fig. 4, ex-
pression levels of p120α in the BPH group were significantly 
higher than those in the NTPC, but not in the PCA-ADT 
group. In contrast, p120β expression levels were significantly 
lower in the BPH group than in the other two NTPC and PCA-
ADT groups. Thus, the β/α ratios were significantly lower 
in the BPH group compared with the NTPC and PCA-ADT 
groups. No significant difference in the expression levels of 
each variant or the ratios in any group in terms of age, pros-
tate-specific antigen levels, or Gleason score were observed. 
DISCUSSION
The nuclear coactivator, p120, has at least two splicing vari-
ants; p120β was cloned and characterized at our university 
[12]. Although p120α acts as a coactivator of many nuclear re-
ceptors, including AR, TR, peroxisome proliferator-activated 
receptor γ, retinoid X receptor, glucocorticoid receptor and 
androgen receptor, the affinity of p120β for AR is strong [12]. 
In the present study, we quantified and compared the expres-
sion levels of both isoforms among prostate cancer cells and 
human prostate tissues. Hosoya et al. [12] using real time 
PCR reported that in prostate tissues p120β expression was 
predominant. They also showed that prostate cancer tissues 
expressed high levels of p120β and that β/α ratios were higher 
in newly diagnosed prostate cancer tissues than in recurrent 
prostate cancer. In the current study, p120α was found to 
predominate in BPH and NTPC samples. These results differ 
from previous reports. One reason for the discrepancy may 
be the quantification method. As mentioned earlier, relative 
expression levels were determined by the band intensity ob-
tained by conventional real time PCR, as reported previously 
[12]. For semiquantification of gene expression levels in real 
time PCR, selection of the optimal cycle number for PCR at 
which transcripts are amplified exponentially is necessary. 
Fig. 3. Comparison of p120α and p120β among the three 
groups. The expression of p120α was significantly higher than 
those of p120β in BPH and NTPC. Bars are expressed as mean± 
standard deviation. BPH, benign prostatic hyperplasia; NTPC, 
nontreated prostate cancer; PCA-ADT, prostate cancer after an-
drogen deprivation therapy. *P<0.05.
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Fig. 4. Comparison of p120α, p120β, and β/α ratios among the 
three groups. The amount of p120α expressed was significantly 
higher in BPH than in the other two groups. p120β expression 
was significantly higher in NTPC and PCA-ADT than in BPH. (A) 
p120α copy number, (B) p120β copy number, and (C) β/α ratio. 
Bars are expressed as mean±standard deviation. BPH, benign 
prostatic hyperplasia; NTPC, nontreated prostate cancer; PCA-
ADT, prostate cancer after androgen deprivation therapy; NS, 
not significant.
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The previous study showed a PCR product profile after 40 
cycles; thus we suggest that the quantification method might 
be the reason for the discrepancy. In the present study, p120α 
and p120β transcripts were detected separately with refer-
ence to the internal controls (Fig. 2). Another reason for the 
discrepancy may be the sample size. We used a large number 
of samples in this study. However, Hosoya et al. [12] evalu-
ated only four non-cancerous tissues, 10 nontreated cancer 
tissues, and three recurrent prostate cancer tissues. To over-
come this limitation of needle biopsy samples, we selected 
patients with multiple positive cores in biopsy samples.
 Another finding of this study was that expression levels of 
p120β, a strong coactivator of AR, were significantly higher 
in the NTPC and PCA-ADT groups compared with the BPH 
group. Of the tested AR coactivators, SRC-1 and TIF-2 ex-
hibited increased expression in CRPC. Protein inhibitor of 
activated STAT-1 and Ran/ara24 exhibited increased expres-
sion in NTPC. RAC-3 (SRC-3) expression was increased in 
poorly differentiated carcinomas and advanced tumors. 
Expression of ELE1/ARA70 in NTPC was decreased, and no 
changes in the expression of other coactivators, including 
ARA54, ARA55, TMF/ARA160, SRC1, and thyroid hormone 
receptor-associated protein 220, between benign prostate 
tissue and NTPC was apparent [15]. The expression profiles 
of p120α and p120β in prostate tissues we report here suggest 
that a nuclear coactivator, in particular, p120β, might play a 
role in prostate cancer. The expression levels of p120α in the 
BPH group were significantly higher than those in the NTPC, 
but not in the PCA-ADT group, while p120β expression levels 
were significantly lower in the BPH group than prostate can-
cer group regardless of previous ADT. These findings might 
suggest that p120β plays a role in the development of prostate 
cancer, while expression of p120α is primarily involved in the 
response of prostate cancer cells to ADT. To explore the exact 
mechanisms underlying the different expression profiles of 
p120, further studies are needed.
 In conclusion, we developed a precise multiplex real time 
PCR method for quantification of p120α and p120β gene 
expression. Prostate tissues, noncancerous or cancerous, 
predominantly expressed p120α over p120β. p120β, which is 
a strong coactivator of the AR, was expressed at significantly 
higher levels in both nontreated and post-ADT prostate can-
cer tissues. These observations suggested that the expression 
profiles of p120α and p120β significantly differ in cancerous 
and benign prostatic tissues.
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